Yueqi Sun

Yueqi Sun

Auto-generated profile, based on publicly available information

Yueqi Sun

Department of Otolaryngology The Seventh Affiliated Hospital of Sun Yat‐sen University Shenzhen China

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2012 in Stem Cells
Verified
Journal Article
Open access
PDF file
YSYue‐Qi Sun
Yue‐Qi Sun
MDMeng‐Xia Deng
Meng‐Xia Deng
JHJia He
Jia He
QZQing‐Xiang Zeng
Qing‐Xiang Zeng
WWWeiping Wen
Weiping Wen
QFQingling Fu
Qingling Fu
We previously found that mesenchymal stem cells (MSCs) derived from human-induced pluripotent stem cells (iPSCs) exerted immunomodulatory effects on Th2-mediated allergic rhinitis in vitro. However, their contribution to the asthma and allergic rhinitis in animal models remains unclear. In this study, we developed a mouse model of ovalbumin (OVA)-induced allergic inflammation in both the upper and lower airways and evaluated the effects of the systemic administration of human iPSC-MSCs and bone marrow-derived MSCs (BM-MSCs) on allergic inflammation. Our results showed that treatments with both the iPSC-MSCs and BM-MSCs before the challenge phase protected the animals from the majority of allergy-specific pathological changes. This protection included an inhibition of inflammatory cell infiltration and mucus production in the lung, a reduction in eosinophil infiltration in the nose, and a decrease in inflammatory cell infiltration in both the bronchoalveolar and nasal lavage fluids. In addition, treatment with iPSC-MSCs or BM-MSCs before the challenge phase resulted in reduced serum levels of Th2 immunoglobulins (e.g., IgE) and decreased levels of Th2 cytokines including interleukin (IL)-4, IL-5, or IL-13 in the bronchoalveolar and/or nasal lavage fluids. Similar therapeutic effects were observed when the animals were pretreated with human iPSC-MSCs before the sensitization phase. These data suggest that iPSC-MSCs may be used as an alternative strategy to adult MSCs in the treatment of asthma and allergic rhinitis. STEM CELLS 2012;30:2692–2699

1 August 2012 in Allergy
Verified
Journal Article
Open access
PDF file
QFQ. L. Fu
Q. L. Fu
YCY. Y. Chow
Y. Y. Chow
SSS. J. Sun
S. J. Sun
QZQ. X. Zeng
Q. X. Zeng
HLH. B. Li
H. B. Li
GXG. Xu
G. Xu
Background: Human induced pluripotent stem cells (iPSCs) possess remarkable self‐renewal capacity and the potential to differentiate into novel cell types, such as mesenchymal stem cells (MSCs). iPSC‐MSCs have been shown to enhance tissue regeneration and attenuate tissue ischaemia; however, their contribution to the immune regulation of Th2‐skewed allergic rhinitis (AR) and asthma remains unclear.Objective: This study compared the immunomodulatory effects of iPSC‐MSCs and bone marrow‐derived MSCs (BM‐MSCs) on lymphocyte proliferation, T‐cell phenotypes and cytokine production in peripheral blood mononuclear cells (PBMCs) in patients with AR, and investigated the possible molecular mechanisms underlying the immunomodulatory properties of iPSC‐MSCs.Methods: In co‐cultures of PBMCs with iPSC‐MSCs or BM‐MSCs, lymphocyte proliferation was evaluated using 3H‐thymidine (3H‐TdR) uptake, carboxyfluorescein diacetate, succinimidyl ester (CFDA‐SE) assays; the regulatory T‐cell (Treg) phenotype was determined by flow cytometry, and cytokine levels were measured using an enzyme‐linked immunosorbent assay. The immunomodulatory properties of both MSCs were further evaluated using NS398 and transwell experiments.Results: Similar to BM‐MSCs, we determined that iPSC‐MSCs significantly inhibit lymphocyte proliferation and promote Treg response in PBMCs (P < 0.05). Accordingly, the cytokine milieu (IFN‐γ, IL‐4, IL‐5, IL‐10 and IL‐13) in the supernatants of PBMCs changed significantly (P < 0.05). The immunomodulatory properties of iPSC‐MSCs and BM‐MSCs were associated with prostaglandin E2 (PGE2) production and cell–cell contact.Conclusions: These data demonstrate that iPSC‐MSCs are capable of modulating T‐cell phenotypes towards Th2 suppression through inducing Treg expansion, suggesting that iPSC‐MSCs can be used as an alternative candidate to adult MSCs to treat allergic airway diseases.

2 March 2017 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
WGWen-Xiang Gao
Wen-Xiang Gao
YSYue-Qi Sun
Yue-Qi Sun
JSJianbo Shi
Jianbo Shi
CLCheng-Lin Li
Cheng-Lin Li
SFShu-Bin Fang
Shu-Bin Fang
QFQingling Fu
Qingling Fu
Mesenchymal stem cells (MSCs) have potent immunomodulatory effects on multiple immune cells and have great potential in treating immune disorders. Induced pluripotent stem cells (iPSCs) serve as an unlimited and noninvasive source of MSCs, and iPSC-MSCs have been reported to have more advantages and exhibit immunomodulation on T lymphocytes and natural killer cells. However, the effects of iPSC-MSCs on dendritic cells (DCs) are unclear. The aim of this study is to investigate the effects of iPSC-MSCs on the differentiation, maturation, and function of DCs. Human monocyte-derived DCs were induced and cultured in the presence or absence of iPSC-MSCs. Flow cytometry was used to analyze the phenotype and functions of DCs, and enzyme-linked immunosorbent assay (ELISA) was used to study cytokine production. In this study, we successfully induced MSCs from different clones of human iPSCs. iPSC-MSCs exhibited a higher proliferation rate with less cell senescence than BM-MSCs. iPSC-MSCs inhibited the differentiation of human monocyte-derived DCs by both producing interleukin (IL)-10 and direct cell contact. Furthermore, iPSC-MSCs did not affect immature DCs to become mature DCs, but modulated their functional properties by increasing their phagocytic ability and inhibiting their ability to stimulate proliferation of lymphocytes. More importantly, iPSC-MSCs induced the generation of IL-10-producing regulatory DCs in the process of maturation, which was mostly mediated by a cell-cell contact mechanism. Our results indicate an important role for iPSC-MSCs in the modulation of DC differentiation and function, supporting the clinical application of iPSC-MSCs in DC-mediated immune diseases.

6 August 2015 in Stem Cells
Verified
Journal Article
Open access
PDF file
YSYue-Qi Sun
Yue-Qi Sun
YZYuelin Zhang
Yuelin Zhang
XLXin Li
Xin Li
MDMeng-Xia Deng
Meng-Xia Deng
WGWen-Xiang Gao
Wen-Xiang Gao
QLQizhou Lian
Qizhou Lian
Adult mesenchymal stem cells (MSCs) are immunoprivileged cells due to the low expression of major histocompatibility complex (MHC) II molecules. However, the expression of MHC molecules in human-induced pluripotent stem cells (iPSCs)-derived MSCs has not been investigated. Here, we examined the expression of human leukocyte antigen (HLA) in human MSCs derived from iPSCs, fetuses, and adult bone marrow (BM) after stimulation with interferon-γ (IFN-γ), compared their repair efficacy, cell retention, inflammation, and HLA II expression in immune humanized NOD Scid gamma (NSG) mice of hind limb ischemia. In the absence of IFN-γ stimulation, HLA-II was expressed only in BM-MSCs after 7 days. Two and seven days after stimulation, high levels of HLA-II were observed in BM-MSCs, intermediate levels were found in fetal-MSCs, and very low levels in iPSC-MSCs. The levels of p-STAT1, interferon regulatory factor 1, and class II transactivator exhibited similar phenomena. Moreover, p-STAT1 antagonist significantly reversed the high expression of HLA-II in BM-MSCs. Compared to adult BM-MSCs, transplanting iPSC-MSCs into hu-PBMNC NSG mice revealed markedly more survival iPSC-MSCs, less inflammatory cell accumulations, and better recovery of hind limb ischemia. The expression of HLA-II in MSCs in the ischemia limbs was detected in BM-MSCs group but not in iPSC-MSCs group at 7 and 21 days after transplantation. Our results demonstrate that, compared to adult MSCs, human iPSC-MSCs are insensitive to proinflammatory IFN-γ-induced HLA-II expression and iPSC-MSCs have a stronger immune privilege after transplantation. It may attribute to a better therapeutic efficacy in allogeneic transplantation. Stem Cells 2015;33:3452–3467

3 May 2024 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
CLChang Liu
Chang Liu
KWKanghua Wang
Kanghua Wang
WLWenqin Liu
Wenqin Liu
JZJinxiu Zhang
Jinxiu Zhang
YFYunping Fan
Yunping Fan
YSYueqi Sun
Yueqi Sun

1 March 2016 in American Journal of Rhinology & Allergy
Verified
Journal Article
Closed access
FCFeng-Hong Chen
Feng-Hong Chen
JDJie Deng
Jie Deng
HHHai-Yu Hong
Hai-Yu Hong
RXRui Xu
Rui Xu
JGJie-Bo Guo
Jie-Bo Guo
JSJian-Bo Shi
Jian-Bo Shi
Background: Functional endoscopic sinus surgery (FESS) is considered to be the standard procedure for chronic rhinosinusitis with nasal polyps (CRSwNP). However, for CRSwNP that accompanies asthma, the results are not satisfying. Extensive endoscopic sinus surgery (EESS) aimed at reducing the inflammatory load has been indicated as a viable option for refractory chronic rhinosinusitis. Objective: To evaluate the clinical outcomes and safety of EESS (middle turbinate and superior turbinate resection and total ethmoidectomy) for patients with CRSwNP and with asthma. Methods: This was a prospective, single-institute cohort study conducted in a tertiary teaching hospital. Patients with CRSwNP and with asthma who were proceeding to surgery were enrolled. There were 23 patients in the EESS group and 24 patients in the FESS group. The preoperative disease severity was evaluated by the visual analog scale (VAS), Lund-Kennedy (L-K) endoscopy score, computed tomography Lund-Mackay score, asthma control test (ACT), and pulmonary function test. Clinical outcomes were comparatively evaluated between the two groups after a 1-year follow-up by using the VAS score, the postoperative endoscopic score (E score), L-K score, ACT score, and pulmonary function test. Results: The disease severity (general VAS score, endoscopic L-K score, computed tomography score, ACT score) showed no significant differences between the two groups before surgery (p > 0.05). One year after surgery, both groups achieved significant improvement in the VAS score and endoscopic L-K score. The EESS group showed better improvement in the olfactory VAS score and E score compared with the FESS group (mean [standard deviation] change of olfactory VAS, 6.00 ∓ 3.67 versus 3.30 ∓ 3.44, p = 0.015; mean [standard deviation] E score, 0.31 ∓ 0.18 versus 0.66 ∓ 0.26, p < 0.001). No significant differences were found in the change of general nasal symptom VAS score, other individual VAS scores (nasal congestion, discharge, headache and/or facial pain), L-K score, ACT score, and pulmonary function between the two groups (p > 0.05). Conclusion: EESS for patients with CRSwNP and with asthma may help to improve the subjective olfaction and endoscopic appearance.